First Innovation Passport awarded to help support development and access to cutting-edge medicines

Belzutifan, developed for adults with von Hippel Lindau disease, has been awarded the first ‘Innovation Passport’ by the MHRA, NICE and SMC. This is the first step in the Innovative Licensing and Access Pathway (ILAP), which will see it accelerated through the approval process

Source:

Medicines and Healthcare products Regulatory Agency